Global Hereditary Angioedema Therapeutics Market - 2021-2028
遺傳性血管性水腫治療的全球市場預計將繼續增長，這得益於對罕見疾病日益增長的興趣以及來自政府和私營公司的研發 (R&D) 資金增加等因素的支持。激肽釋放酶抑製劑就藥物類別、就給藥途徑的靜脈 (IV) 注射和就治療類型的按需治療佔最大佔有率。就地區來看，北美國家是最大的市場，預計將引領未來的市場增長。
The global hereditary angioedema therapeutics market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Hereditary Angioedema is a rare genetic disorder typically characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling most commonly affects the arms, intestinal tract, legs, face, and airway and is usually not itchy.
The hereditary angioedema therapeutics market growth is driven by the growing awareness of the treatment for rare diseases, increasing funding for rare genetic diseases and orphan drugs by the government and private companies and the rising cases of hereditary angioedema (HAE) are key factors driving the growth of the market.
Growing awareness of the treatment for rare diseases, is expected to drive the global hereditary angioedema therapeutics market growth
The primary factor attributing to the market's growth is the increasing awareness of the treatment for rare diseases such as hereditary angioedema (HAE). According to the National Organization for Rare Disorders (NORD), the condition is believed to affect about 1 in 50,000 people, and 1 in 150,000 individuals are affected by this disorder worldwide. Angioedema attacks usually occur in sudden, regularly painful swelling in numerous parts of the body, involving the abdomen, extremities, throat, and face. Many organizations are spreading awareness about the diseases and their treatment, like the US Hereditary Angioedema Association, a non-profit organization dedicated to offering HAE patients access to the latest treatment options and dependable, personal support to address symptoms challenges associated with the condition. As per an article published on the National Library of Medicine in October 2020, a study was conducted in 2020 to evaluate the current HAE management and the new treatment options on physician practice patterns over time. The study suggested that physicians reported improvements in HAE management in recent years as per the survey conducted in the United States. Owing to the current therapeutic advances, the reported cases of HAE have improved and reduced concern of adverse treatment effects, and high levels of patient satisfaction have been observed.
Increasing funding for rare genetic diseases and orphan drugs by the government and private companies, is expected to drive the global hereditary angioedema therapeutics market growth
Rising funding for rare genetic diseases and orphan drugs by the government and private companies is also enhancing the interest of the pharmaceutical companies to develop drugs for hereditary angioedema and fuel the market's growth. For example, the Indian Ministry of Health and Family Welfare initiated a National Policy to treat rare diseases in India to expand India's capabilities to treat rare diseases progressively. The Indian ministry released funding of an initial amount of INR 100 crore to treat rare genetic diseases. Hence, the growing funding for research and development for new drugs is boosting the market growth.
For instance, in November 2020, Takeda Pharmaceutical agreed to public funding in Canada of Takhzyro (lanadelumab), its treatment for eligible hereditary angioedema (HAE) patients. In addition, the National Institutes of Health (NIH) also supports research to improve people's health with rare diseases. Many of the 27 Institutes and Centers receives NIH fund for medical research of rare diseases.
Misdiagnosis of the condition due to lack of knowledge of disorder is likely to hamper the market growth
The misdiagnosis of the condition, as common allergies, appendicitis, and irritable bowel syndrome, has steered to an interruption ineffective treatment, which in turn, leads to inadequate treatment being provided to patients, which has had a considerable negative impact on the growth of the global hereditary angioedema therapeutics market.
COVID-19 Impact Analysis
Due to the present pandemic situation, there is a continuous urge to develop a treatment and vaccine; pharmaceutical companies have dedicated their R&D resources entirely to support the COVID-19 vaccine development. In addition, research and development activities for rare diseases, like hereditary angioedema, have been outlined for the time being in R&D laboratories. Moreover, some companies are focusing their R&D resources to understand the effect of COVID-19 in a patient with rare diseases and carrying out Esoteric Testing to determine novel therapies for COVID-19 patients.
The kallikrein inhibitors segment is expected to hold largest share in this market segment
Kallikrein Inhibitors are expected to hold the largest share of the segment over the forecast period. Currently, various kallikrein inhibitors are being evaluated owing to their potential to prevent edematous HAE attacks. This comparatively emerging drug therapy class has several potential molecules in the pipelines, which is expected to fuel the market growth.
For instance, BioCryst is developing a novel treatment to treat and prevent angioedema attacks in patients with hereditary angioedema (HAE) and evaluate the molecule APeX-1, an oral once-daily, selective inhibitor of plasma kallikrein. Also, the pharmaceutical companies are rapidly seeking approval in this class of drugs as there is comparatively less competition in this market space.
For instance, in August 2020, the United States Food and Drug Administration approved Takhzyro (lanadelumab), the first monoclonal antibody that targets Kallikrein and is indicated to treat patients 12 years and older types I and II HAE.
The On-demand treatment segment is expected to hold largest share in this market segment
Continued use of on-demand products to manage acute hereditary angioedema attacks is a high-impact rendering driver for the hereditary angioedema therapeutics market.
Moreover, the geographical expansion of companies in newer markets is likely to profound the segment growth. For instance, in September 2018, Shire plc announced that it had received marketing authorization from Japan's Ministry of Health, Labor and Welfare (MHLW) for Firazyr used in the on-demand treatment of hereditary angioedema.
The intravenous segment is expected to hold largest share in this market segment
For medications used to treat hereditary angioedema disorder, intravenous administration has become the most preferred mode of administration. This is because traditional prophylactic medications have historically been given intravenously due to advantages such as convenient dosing and superior efficacy compared to the oral form.
North America region holds the largest market share of global hereditary angioedema therapeutics market
The North American region is expected to serve a large share of the hereditary angioedema market over the forecast period. The market growth is due to key players' presence, increasing awareness programs and research organizations regarding the treatment of the condition, and established healthcare infrastructure. Furthermore, the increasing government initiatives, rising research partnerships, and a robust pipeline are the major growth boosters of the market. For instance, Ionis Pharmaceuticals, a biotechnology company based in California, currently has IONIS-PKK-LRx, a ligand-conjugated (LICA) investigational antisense medicine in its pipeline completed its Phase 2 trials. The company is developing the drug molecule to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema. Also, there is a large number of government and non-government-funded research institutions in this region. For instance, the National Center for Advancing Translational Sciences (NCATS) is wholly focused on esoteric testing for the cure and treatments for rare diseases. NCATS aims to get collaborative projects to study common themes and causes of related diseases to speed the development of treatments. Hence, owing to all the factors mentioned above, the market is anticipated to have lucrative growth in the future.
The global hereditary angioedema therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CSL Behring LLC, Takeda Pharmaceutical Company, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Adverum Biotechnologies, Inc, Arrowhead Pharmaceuticals, Sanofi, Advanced Technology & Industrial Co., Ltd, GL Biochem (Shanghai) Ltd, Ontores Biotech, Shanghai Qiming Biological Technology Co., Ltd, Hangzhou Peptidego Biotech Co.,Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In February 2021, KalVista reported positive results in our Phase 2 clinical trial for KVD900 as an oral on-demand treatment for HAE attacks.
Key Companies to Watch
BioCryst Pharmaceuticals, Inc
Overview: BioCryst is a commercial-stage biotech company committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, they are passionate about advancing novel therapeutics for patients with severe and rare diseases. Its US headquarters are located in Durham, North Carolina, and its European headquarters in Dublin, Ireland. Its expertise in drug discovery, clinical development, and regulatory affairs is advancing clinical programs and generating new compounds from its discovery engine.
Product Portfolio: The company is focused primarily on Structure-guided drug design and rare disease therapeutics.
Key Development: In February 2021, BioCryst Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the approval of ORLADEYO (berotralstat) for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12*years and older.
The global hereditary angioedema therapeutics market report would provide an access to an approx. 61 market data table, 52 figures and 200 pages.
Global Hereditary Angioedema Therapeutics Market - By Drug Class
Global Hereditary Angioedema Therapeutics Market - By Treatment Type
Global Hereditary Angioedema Therapeutics Market - By Route of Administration
Global Hereditary Angioedema Therapeutics Market - By Region
LIST NOT EXHAUSTIVE